MX354615B - Use of propylparaben as neuroprotective agent to attenuate brain damage produced by status epilepticus. - Google Patents

Use of propylparaben as neuroprotective agent to attenuate brain damage produced by status epilepticus.

Info

Publication number
MX354615B
MX354615B MX2013011437A MX2013011437A MX354615B MX 354615 B MX354615 B MX 354615B MX 2013011437 A MX2013011437 A MX 2013011437A MX 2013011437 A MX2013011437 A MX 2013011437A MX 354615 B MX354615 B MX 354615B
Authority
MX
Mexico
Prior art keywords
propylparaben
status epilepticus
brain damage
neuroprotective agent
damage produced
Prior art date
Application number
MX2013011437A
Other languages
Spanish (es)
Other versions
MX2013011437A (en
Inventor
Lilia Rocha Arrieta Luisa
Emmanuel Santana Gómez César
Bruno Blanch Luis
Adela Orozco Suárez Sandra
Talevi Alan
Leticia Bellera Carolina
Original Assignee
Centro De Investig Y De Estudios Avanzados Del I P N
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro De Investig Y De Estudios Avanzados Del I P N filed Critical Centro De Investig Y De Estudios Avanzados Del I P N
Priority to MX2013011437A priority Critical patent/MX354615B/en
Priority to PCT/IB2014/064484 priority patent/WO2015049608A1/en
Publication of MX2013011437A publication Critical patent/MX2013011437A/en
Publication of MX354615B publication Critical patent/MX354615B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention describes the use of propylparaben, a widely known antimicrobial, for decreasing neuronal injury induced by Status epilepticus. An objective of the invention is the administration of propylparaben immediately after the occurrence of Status epilepticus to prevent neuronal injury and the possible development of epileptogenesis, as well the neurocognitive disorders associated with this condition.
MX2013011437A 2013-10-02 2013-10-02 Use of propylparaben as neuroprotective agent to attenuate brain damage produced by status epilepticus. MX354615B (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
MX2013011437A MX354615B (en) 2013-10-02 2013-10-02 Use of propylparaben as neuroprotective agent to attenuate brain damage produced by status epilepticus.
PCT/IB2014/064484 WO2015049608A1 (en) 2013-10-02 2014-09-13 Use of propylparaben as neuroprotective agent to attenuate brain damage produced by status epilepticus

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2013011437A MX354615B (en) 2013-10-02 2013-10-02 Use of propylparaben as neuroprotective agent to attenuate brain damage produced by status epilepticus.

Publications (2)

Publication Number Publication Date
MX2013011437A MX2013011437A (en) 2015-04-10
MX354615B true MX354615B (en) 2018-03-08

Family

ID=52778314

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013011437A MX354615B (en) 2013-10-02 2013-10-02 Use of propylparaben as neuroprotective agent to attenuate brain damage produced by status epilepticus.

Country Status (2)

Country Link
MX (1) MX354615B (en)
WO (1) WO2015049608A1 (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2114405B1 (en) * 2006-12-28 2015-03-11 F. Hoffmann-La Roche AG methylparaben cocrystal form "A" of [4-(3-Fluoro-5-trifluoromethyl-pyridin-2-yl)-piperazin-l-yl]-[5-methanesulfonyl-2- ((S) -2,2,2-trifluoro- 1 -methyl-ethoxy) -phenyl] -methanone
KR101196354B1 (en) * 2010-09-03 2012-11-01 서유헌 Pharmaceutical composition for prevention or treatment of neurodegenerative brain diseases

Also Published As

Publication number Publication date
MX2013011437A (en) 2015-04-10
WO2015049608A1 (en) 2015-04-09

Similar Documents

Publication Publication Date Title
ZA201701299B (en) Glycosidase inhibitors
PH12015502658A1 (en) 3,4-dihydroisoquinolin-2 (1h)-yl compounds
HK1219943A1 (en) Substituted 3-phenylpropylamine derivatives for the treatment of ophthalmic diseases and disorders 3-
HUE056006T2 (en) Combination for the treatment of parkinson's disease
BR112016027048A2 (en) Use of a compound of formula I in the treatment of brain cancer and glioblastoma multiforme mgmt positive
MX2016013280A (en) Topical compositions for pain relief, manufacture and use.
BR112018071560A2 (en) compounds and methods for treating neurological and cardiovascular conditions
CA2909956C (en) Accelerated healing of eye injuries by angiotensin peptides
MX2016009794A (en) Heterocyclic sulfonamide derivative and medicine comprising same.
BR112016023491A2 (en) methods for the protection and treatment of traumatic brain injury, concussion and brain inflammation with intranasal insulin.
HK1218703A1 (en) Device providing enlargement & preventing collapse of the pupil of the eye
MX2016010085A (en) Methods of treating mild brain injury.
TN2015000558A1 (en) Use of sigma receptor ligands for the prevention and treatment of pain associated to interstitial cystitis/bladder pain syndrome (ic/bps)
SG10202001157XA (en) Medical needle with protector
WO2015066302A3 (en) Compositions, methods of use, and methods of treatment
PH12016501173A1 (en) Quinazolin-thf-amines as pde1 inhibitors
IL242355B (en) Cannabidiol for the prevention and treatment of graft-versus-host disease
EP3190887A4 (en) Methods for treating and preventing ocular diseases, disorders, and conditions with melanin and melanin analogs, precursors, and derivatives
GEP20186920B (en) Halogenated quinazolinthf-amines as pde1 inhibitors
MX354615B (en) Use of propylparaben as neuroprotective agent to attenuate brain damage produced by status epilepticus.
WO2015181837A3 (en) Novel compounds as anti-tubercular agents
MA51281A (en) ADVANCED SAFETY CATHETER NEEDLE
BR112017005168A2 (en) c-20 steroid compounds, compositions and uses thereof to treat traumatic brain injury (tbi), including concussions
EP3612257A4 (en) Passive safety needle shield
DK3148588T3 (en) N,n-bis-2-mercaptoethyl isophthalamide for the treatment of parkinson's disease

Legal Events

Date Code Title Description
FG Grant or registration